Interesting theory, however, the company is likely to pump all profits into exploration and paying off remaining debt.The stock is currently providing an entry or top-up price that was not expected and may never be repeated.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%